- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- OncNursingNews.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Multiple Myeloma | Clinical
test
Daratumumab With Bortezomib and Dexamethasone Improves Survival in RRMM
December 02, 2022
Patients with multiple myeloma administered daratumumab in combination with bortezomib and dexamethasone demonstrated improvements in overall survival compared with those given bortezomib and dexamethasone alone.
COMING SOON: The Role of BCMA-Directed Therapy in Relapsed/Refractory Multiple Myeloma
December 01, 2022
Sagar Lonial, MD, FACP, provides a look at an upcoming Virtual Tumor Board program on BCMA-directed therapies in relapsed/refractory multiple myeloma treatment.
CAR T Cells are Taking Hold in the Multiple Myeloma Space
December 01, 2022
In an interview with Targeted Oncology, Christopher R. D’Angelo, MD discussed recent approvals in the multiple myeloma space and how to treat patients using immunotherapy.
Clinical Commentary: Dose Reduction of Selinexor in Relapsed Patients With Multiple Myeloma
November 29, 2022
At a live virtual event, Sumit Madan, MD, broke down the use of quadruplet therapies in the frontline setting for patients with multiple myeloma and how to care for patients when they relapse on treatment.
Goals and Efficacy of the MajesTEC-1 Trial in Multiple Myeloma
November 23, 2022
Thomas G. Martin, MD, discusses the goals and efficacy outcomes of the phase 1/2 MajesTEC-1 trial of teclistamab-cqyv for patients with relapsed/refractory multiple myeloma.
Efebera Discusses Different Regimens for Transplant-Eligible NDMM
November 23, 2022
During a Targeted Oncology case-based roundtable event, Yvonne A. Efebara, MD, MPH, discussed the role of triplet and quadruplet systemic therapies for newly diagnosed multiple myeloma and the use of autologous stem cell transplant.
FDA Requests Belantamab Mafodotin for R/R Multiple Myeloma Be Pulled From US Market
November 22, 2022
After an update from the phase 3 DREAMM-3 study the use of belantamab monotherapy for previously treated patients with relapsed or refractory multiple myeloma was pulled from US market authorization by request of the FDA.
Forsberg Explains How Selinexor Fits Into Sequencing Therapies in R/R Multiple Myeloma
November 16, 2022
During a Targeted Oncology case-based roundtable event, Peter Forsberg, MD, discussed data from several trials of selinexor in patients with relapsed/refractory multiple myeloma.
Comparing Latest Evidence for Therapies in Newly Diagnosed Multiple Myeloma
November 09, 2022
During a Targeted Oncology case-based roundtable event, Adam Binder, MD, discussed trials supporting triplet and quadruplet regimens along with autologous stem cell transplant.
Treatment Possibilities for R/R Multiple Myeloma After BCMA-Directed CAR T-Cell Therapy
November 07, 2022
Retrospective real-world evidence shows that patients who relapse after B-cell maturation antigen chimeric antigen receptor T-cell therapy may have multiple treatment options, including salvage therapy and T-cell engagers.